In the past 12 months the Corneal Inlays for Presbyopia Correction industry trends have accelerated through a blend of strategic alliances and regulatory milestones. In March, Johnson & Johnson Vision announced a partnership with Japan’s Santen Pharma to co‑develop a next‑generation, light‑adjustable inlay, aiming to shorten the learning curve for surgeons. Alcon completed its acquisition of U.S. startup ClearFocus in June, securing proprietary femtosecond‑laser integration technology that promises sub‑micron placement accuracy. A hydrogel‑based inlay, FlexiVision, received CE‑Mark clearance in September and launched across Europe, highlighting a shift toward softer, reversible materials. The U.S. FDA granted pre‑market approval for a diffractive‑ring design in November, expanding the therapeutic arsenal for patients seeking same‑day correction. Concurrently, the European Medicines Agency revised post‑market surveillance rules, tightening reporting timelines for adverse events. Consumer preference is moving toward minimally invasive, “drop‑in” solutions, prompting a €45 million Series C round for Shanghai‑based NovaLens, which is also opening a new manufacturing hub in Pune, India to meet rising demand.